Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2611 to 2625 of 8224 results

  1. Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]

    Awaiting development Reference number: GID-TA11215 Expected publication date:  07 May 2026

    Technology appraisal guidance
    Awaiting development

  2. AI software for electroencephalogram (EEG) interpretation in epilepsy

    In development Reference number: GID-HTE10086 Expected publication date: TBC

    Health technology evaluations
    In development

  3. Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA779) [ID6326]

    In development Reference number: GID-TA11764 Expected publication date:  23 July 2026

    Technology appraisal guidance
    In development

  4. Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 3 February 2026.

    Technology appraisal guidance
    In consultation

  5. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development Reference number: GID-TA11220 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 15 January 2026.

    Technology appraisal guidance
    In consultation

  7. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update): draft guidance consultation

    We are listening to your views on this NICE guideline. Comments close 23 February 2026.

    NICE guideline
    In consultation

  8. Prognostic tests for multiple myeloma

    Awaiting development Reference number: GID-HTG10153 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  9. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)

    In development Reference number: GID-NG10216 Expected publication date:  15 July 2026

    NICE guideline
    In development

  10. Blood transfusion - Tranexamic acid (update)

    In development Reference number: GID-NG10441 Expected publication date:  26 February 2026

    NICE guideline
    In development

  11. Nivolumab in combination for untreated advanced classical Hodgkin lymphoma in people 12 years and over [ID6690]

    Awaiting development Reference number: GID-TA11908 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Nivolumab + Brentuximab vedotin for Hodgkin lymphoma [ID6691]

    Awaiting development Reference number: GID-TA11909 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Obinutuzumab for treating childhood-onset idiopathic nephrotic syndrome in people 2 years and over [ID6692]

    Awaiting development Reference number: GID-TA11910 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Medicines for treating osteoporosis and reducing the risk of fragility fractures (review of TA160, TA161, TA204, TA464, TA791, TA991) [ID6689]

    Awaiting development Reference number: GID-TA11907 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]

    In development Reference number: GID-TA10979 Expected publication date:  11 March 2026

    Technology appraisal guidance
    In development